Back to top

Chemours (CC) Q3 Earnings Beat, Revenues Trail Estimates

Read MoreHide Full Article

The Chemours Company (CC - Free Report) logged a profit of $275 million or $1.51 per share in the third quarter of 2018, up from $207 million or $1.08 a year ago. Adjusted earnings came in at $1.49 per share, which topped the Zacks Consensus Estimate of $1.38.

Net sales rose around 3% year over year to $1,628 million, mainly driven by strong demand in Fluoroproducts and higher global average selling prices in Titanium Technologies. However, the figure trailed the Zacks Consensus Estimate of $1,715.8 million.

The company recorded adjusted EBITDA of $435 million in the quarter, up 14% year over year. The results were driven by higher sales, partly offset by increased raw material costs.

Chemours Company (The) Price, Consensus and EPS Surprise


Chemours Company (The) Price, Consensus and EPS Surprise | Chemours Company (The) Quote


Segment Highlights

Revenues in the Fluoroproducts segment rose 7% year over year to $682 million. Broad-based demand for Opteon and base refrigerants as well as fluoropolymer products boosted sales in the quarter.

Revenues in the Chemical Solutions unit amounted to $155 million, up 5% year over year. Weaker demand for intermediates products and performance chemicals affected the segment’s volumes.

Revenues in the Titanium Technologies division were $791 million, slightly down from $799 million in the prior-year quarter. Volume was lower compared to strong demand in the prior-year quarter, resulting from sustained inventory destocking by customers.


As of Sep 30, Chemours had cash and cash equivalents of $1,275 million, down roughly 16.9% year over year. Long-term debt was $3,985 million, down around 2.4% year over year.
The company generated operating cash flow of $342 million in the quarter, up more than three-fold year over year. Free cash flows for the quarter was around $226 million, down 30.2% from the year-ago quarter's tally. Capital expenditures were $116 million, up from $108 million in the year-ago quarter.

Chemours repurchased roughly $136 million of stock during the third quarter.


Going forward, the company expects each of the segments to deliver solid year-over-year top- and bottom-line growth. For Fluoroproducts, it expects results to improve on the back of continued adoption of Opteon refrigerants and strong demand for fluoropolymers products. Moreover, Chemical Solutions unit is projected to continue to delivering improved performance driven by strong demand for mining solutions products. Chemours expects the Titanium Technologies segment to witness year-over-year improvement, despite expected volume loss due to customer destocking.

Chemours expects adjusted EBITDA within the lower half of its original guidance of $1.70-$1.85 billion. Free cash flow is expected to be roughly $650 million for 2018. Adjusted earnings per share are forecasted in the range of $5.10-$5.85.

Price Performance

Chemours’ shares lost around 25.9% in the past three months compared with roughly 19.5% decline recorded by its industry.



Zacks Rank & Stocks to Consider

Chemours currently carries a Zacks Rank #5 (Strong Sell).

A few better-ranked stocks in the basic materials space are Methanex Corporation (MEOH - Free Report) and CF Industries Holdings, Inc. (CF - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) as well as KMG Chemicals, Inc. carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Methanex has expected long-term earnings growth rate of 15%. Its shares have rallied 23.5% in the past year.

CF Industries has expected long-term earnings growth rate of 6%. Its shares have gained 26.7% in a year.

KMG Chemicals has expected long-term earnings growth rate of 28.5%. Its shares have rallied 43.2% in the past year.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

The Chemours Company (CC) - free report >>

Methanex Corporation (MEOH) - free report >>

CF Industries Holdings, Inc. (CF) - free report >>

More from Zacks Analyst Blog

You May Like